Furthermore, in the second term of 2020, six clinical trials of patients with chronic kidney disease (CKD) or heart failure with or without diabetes showed that the SGLT2 inhibitors dapagliflozin and empagliflozin exhibited cardiorenal protective effects [13,14,15,16,17,18]. Here, SLC5A2 is linked to heart failure.